TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis using consensus grading with steroid-resistant Grade II-IV acute GvHD, after a haematopoietic stem cell transplant for a haematological disorder.~* Life expectancy of at least one month.~* Agree to have follow-up data collected for two years after their initial dose of CYP-001 (under a separate protocol).~Exclusion Criteria:~* Pregnant or breastfeeding or plan to become pregnant within three months of receiving their last dose of CYP-001.~* Have received any investigational research agent within 30 days or five half-lives (whichever is longer) prior to the first dose of IMP.~* Known or suspected current alcohol or substance abuse problem.~* Progressive or relapsing haematological malignancy, a current solid tumour, or previous malignant solid tumour that is likely to recur during the period of the study (with the exception of a past history of basal or squamous cell carcinomas).~* Heart failure (NYHA Functional Class II-IV) and/or pulmonary failure.~* Haemodynamically unstable and/or at high risk of cardiovascular events.~* Terminal organ failure.~* Meningitis, pneumonia with hypoxemia, HIV or another severe or uncontrolled systemic infection, which in the opinion of the investigator is likely to impact on the ability of the patient to participate in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
- Cohort B (Type: EXPERIMENTAL): Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with history of sleeplessness~Exclusion Criteria:~* Allergic to investigational drug~* Any conditions and medications that may interfere with study drug evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Zolpidem 3.5mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Symptoms and signs of acute pancreatitis based on abdominal pain suggestive of AP, serum amylase at least three times the upper limit of normal, and/or characteristic findings of AP on computed tomography or less commonly magnetic resonance imaging (MRI) or transabdominal ultrasonography according to the Revised Atlanta Criteria\[15\];~2. Less than one week from the onset of abdominal pain;~3. Age between 18 to 70 years old;~4. Acute Physiology and Chronic Health Evaluation(APACHE II) score ≥8 during the last 24 hours before enrollment~5. Balthazar CT score ≥5 (presence of pancreatic necrosis)\[16\].~6. Written informed consent obtained~Exclusion criteria~1. Pregnant pancreatitis;~2. History of chronic pancreatitis；~3. Malignancy related acute pancreatitis~4. Receiving early intervention or surgery due to abdominal compartment syndrome or other reasons before admission；~5. Patients with a known history of severe cardiovascular, respiratory, renal or hepatic diseases defined as (1) greater than New York Heart Association Class II heart failure(Class II not included), (2) active myocardial ischemia or (3) cardiovascular intervention within previous 60 days, (4) history of cirrhosis or (5) chronic kidney disease with creatinine clearance\< 40 mL/min, or (6) chronic obstructive pulmonary disease with requirement for home oxygen;~6. Patients with preexisting immune disorders such as AIDS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin (Type: EXPERIMENTAL): Thymosin alpha 1 has been shown to have immunomodulatory properties
- Placebo (Type: PLACEBO_COMPARATOR): normal saline;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants chronically infected with hepatitis C virus (HCV) genotype 2 or 3~* No previous exposure to an interferon formulation (ie, interferon alfa, pegylated interferon alfa-2a ) or ribavirin~* Body mass index (BMI) of 18 to 35 kg/m\^2, inclusive. BMI=weight (kg)/height (m)\^2~* Males and females, 18 - 70 years of age~Key Exclusion Criteria:~* Liver transplant recipients~* Documented or suspected hepatocellular carcinoma~* Evidence of decompensated cirrhosis~* History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may participate~* Current or known history of cancer~* Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug~* Inability to tolerate oral medication~* Poor venous access~* Severe psychiatric disease~* History of chronic pulmonary disease~* History of cardiomyopathy, coronary artery disease (including angina), interventive procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant cardiac disease~* History of or current electrocardiogram findings indicative of cardiovascular instability~* Preexisting ophthalmologic disorders considered clinically significant on eye~* History of uncontrolled diabetes mellitus~* Any known contraindication to pegylated interferon alfa-2a or ribavirin not otherwise specified.~* Positive hepatitis B virus surface antigen, HIV-1 or HIV-2 Ab~* Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase, previous nonstructural protein 5A inhibitors)~* Exposure to any investigational drug or placebo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Placebo + Pegylated interferon alfa-2a + Ribavirin
- 12 Week Cohort (Type: EXPERIMENTAL): Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
- 16 Week Cohort (Type: EXPERIMENTAL): Daclatasvir + Pegylated interferon alfa-2a + Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Females 18 years of age and older at screening.~2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.~3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.~4. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.~Exclusion Criteria:~1. Subjects who, in the opinion of the study site principal investigator, have a high-risk pregnancy.~2. Subjects with a pregnancy-induced medical condition or complication.~3. Subjects with 3 or more prior C-sections.~4. Pre-pregnancy body mass index \>50 kg/m2.~5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications.~6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.~7. Severely impaired renal or hepatic function.~8. Subjects at an increased risk for bleeding or a coagulation disorder.~9. Concurrent painful physical condition that may require analgesic treatment in the postsurgical period for pain that is not strictly related to the surgery.~10. Clinically significant medical disease in either the mother or baby that, in the opinion of the investigator, would make participation in a clinical study inappropriate.~11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.~12. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug.~13. Previous participation in an EXPAREL study.~14. Any clinically significant event or condition uncovered during the surgery that might render the subject medically unstable or complicate the subject's postsurgical course.~15. Receives the epidural component of combined spinal epidural (CSE) anesthesia during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Standard of Care Group) (Type: ACTIVE_COMPARATOR): 150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
- Group 2 (Duramorph + EXPAREL TAP) (Type: EXPERIMENTAL): 50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
- Group 3 (EXPAREL TAP) (Type: EXPERIMENTAL): EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients (male or female) 18 years of age or older.~* Horizontal forehead lines (HFL), glabellar frown lines (GFL), and symmetrical lateral canthal lines (LCL) of moderate to severe intensity at maximum contraction as assessed by the investigator and subject according to Merz Aesthetics Scales (MAS).~Exclusion Criteria:~* Previous treatment with botulinum neurotoxin (BoNT) of any serotype in the face within the last 12 months before injection.~* Any facial cosmetic procedure within the last 12 months before baseline injection.~* Previous treatment with any biodegradable filler in the face within the last 12 months before injection.~* Any previous insertion of permanent material in the face (regardless of the time between previous treatment and this study).~* Any medical condition that may put the subject at increased risk with exposure to NT201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main Period: Placebo (Group P) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.
- Main Period: NT 201 (Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
- Main Period: NT 201 and Placebo (Group L) (Type: EXPERIMENTAL): Subjects will receive a total of 24 U NT 201: placebo injection both in the GFL and HFL area, and 24 U NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
- OLEX: NT 201 (Main Period: Group P) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group L) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who underwent delivery either by elective or emergent cesarean section at 24 week gestation or later with preoperative levels of hemoglobin and hematocrit determined up to 72 hours prior to delivery. The patients must have at least one of the risk factors for uterine atony listed below:~  1. Fetal macrosomia (estimated fetal weight ≥ 4 Kilos) diagnosed by clinical measurement (Johnson´s technique) or ultrasound measurement (Hadlock´s formula).~ 2. Polyhydramnios (defined as Phelan´s amniotic fluid index \> 24 cm)~ 3. Twin or Multiple pregnancy.~ 4. Prolonged labour (prolonged active phase \> 12 hours) or precipitate labour(cervical dilatation ≥ 10 cm/hour).~ 5. Magnesium sulphate or any other tocolytic agent therapy for ≥ 8 hours before cesarean section.~ 6. Intravenous oxytocin therapy for at least 4 hours before cesarean section.~ 7. Multiparous women (≥ 3 prior abdominal or vaginal deliveries )~ 8. Clinical chorioamnionitis was defined as maternal temperature of ≥ 38°C in addition to more than one of the following criteria: fetal tachycardia (\> 160 beats per minute), maternal tachycardia (\>100 beats per minute, maternal leukocytosis (15,000 cells/mm3), uterine tenderness or foul smelling amniotic fluid.~ 9. Known myomatosis, uterine Müllerian malformations or those diagnosed by ultrasound.~Exclusion Criteria:~1. Misoprostol incorrect administration~2. Severe allergic, bleeding disorders (e.g., haemophilia); severe asthma or any other absolute contraindication to misoprostol use.~3. Any bleeding occurred before delivery (abruptio placentae, placenta praevia) or bleeding due to other causes different than uterine atony.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
- Folic Acid (Type: PLACEBO_COMPARATOR): women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* At least one prescription for bazedoxifene, raloxifene, or any bisphosphonate during the study inclusion period (index prescription);~* A recoded diagnosis code of osteoporosis on or within 60 days prior to the index prescription date;~* Age \>=45 at the date of the index prescription; and~* At least 6-months of follow-up data in the electronic medical record system prior to the date of the index prescription~Exclusion Criteria:~* There is no exclusion criteria. All women in the database who meet the inclusion criteria will be studied.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bazedoxifene (Type: None): None
- Primary Comparator (Type: None): None
- Secondary Comparator (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erector Spinae Plane Block For Lumbar Disc Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* Age 18-65 years~* Undergoing elective lomber disc hernia~Exclusion Criteria:~* obesity~* ASA III - IV~* infection of the skin at the site of needle puncture area~* patients with known allergies to any of the study drugs~* coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erector Spinae Plane Block (Type: ACTIVE_COMPARATOR): Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks
- Control Group (Type: SHAM_COMPARATOR): Sham block will be done with serum physiologic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written Informed Consent~* 6-11 years old, either sex, either race~* If female, subject to be premenarcheal~* Willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.~* Free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.~* Able to adhere to the dosing and visit schedules~Exclusion Criteria:~* If female, subject who was pregnant, intended to become pregnant during the study or nursing.~* Subject had used any investigational product within 30 days prior to enrollment.~* Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.~* Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).~* Subject was participating in any other clinical study(ies).~* Subject was part of the staff or a family member of the staff personnel directly involved with this study.~* Subject was allergic to or has sensitivity to the study drug or its excipients.~* Subject had a history of allergic reaction to prescription and/or over the counter (OTC) medications and/or food products.~* Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.~* Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- RediTab/Zyrtec (Type: ACTIVE_COMPARATOR): Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
- Zyrtec/RediTab (Type: ACTIVE_COMPARATOR): Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete